| Literature DB >> 32778736 |
Luciano J Costa1, Benjamin A Derman2, Susan Bal3, Surbhi Sidana4, Saurabh Chhabra5, Rebecca Silbermann6, Jing C Ye7, Gordon Cook8, Robert F Cornell9, Sarah A Holstein10, Qian Shi11, James Omel12, Natalie S Callander13, Wee Joo Chng14, Vania Hungria15, Angelo Maiolino16, Edward Stadtmauer17, Sergio Giralt18, Marcelo Pasquini5, Andrzej J Jakubowiak2, Gareth J Morgan19, Amrita Krishnan20, Graham H Jackson21, Mohamad Mohty22, Maria Victoria Mateos23, Meletious A Dimopoulos24, Thierry Facon25, Andrew Spencer26, Jesus San Miguel27, Parameswaran Hari5, Saad Z Usmani28, Salomon Manier29, Phillip McCarthy30, Shaji Kumar31, Francesca Gay32, Bruno Paiva27.
Abstract
Minimal residual disease (MRD) assessment is incorporated in an increasing number of multiple myeloma (MM) clinical trials as a correlative analysis, an endpoint or even as a determinant of subsequent therapy. There is substantial heterogeneity across clinical trials in how MRD is assessed and reported, creating challenges for data interpretation and for the design of subsequent studies. We convened an international panel of MM investigators to harmonize how MRD should be assessed and reported in MM clinical trials. The panel provides consensus on which MM trials should include MRD, the recommended time points for MRD assessment, and expected analytical validation for MRD assays. We subsequently outlined parameters for reporting MRD results implementing the intention-to-treat principle. The panel provides guidance regarding the incorporation of newer peripheral blood-based and imaging-based approaches to detection of residual disease. Recommendations are summarized in 13 consensus statements that should be followed by sponsors, investigators, editors, and reviewers engaged in designing, performing, and interpreting MM trials.Entities:
Mesh:
Year: 2020 PMID: 32778736 DOI: 10.1038/s41375-020-01012-4
Source DB: PubMed Journal: Leukemia ISSN: 0887-6924 Impact factor: 11.528